ProCE Banner Activity

PEACE-1: Phase III Trial of Abiraterone With or Without Local Radiotherapy + SoC in de novo Metastatic Castration-Sensitive Prostate Cancer

Slideset Download
Conference Coverage
In patients with metastatic castration-sensitive prostate cancer, the addition of abiraterone to standard of care, ADT with or without docetaxel, prolonged median radiographic PFS by more than 2 years.

Released: June 17, 2021

Expiration: June 16, 2022

No longer available for credit.

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie

Amgen, Inc.

AstraZeneca

Bristol Myers Squibb

Daiichi Sankyo, Inc.

Exelixis

Gilead Sciences, Inc.

GlaxoSmithKline

Ipsen Biopharmaceuticals Inc

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation

Pfizer, Inc.

Pharmacyclics LLC an AbbVie Company and Janssen Biotech Inc

Sanofi Genzyme